采用重组蛋白免疫印迹法检测原发性感染患者对人细小病毒B19的抗体反应。
Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins.
作者信息
Palmer P, Pallier C, Leruez-Ville M, Deplanche M, Morinet F
机构信息
Unité de Virologie, Hôpital Saint-Louis, Paris, France.
出版信息
Clin Diagn Lab Immunol. 1996 Mar;3(2):236-8. doi: 10.1128/cdli.3.2.236-238.1996.
Abstract
Human parvovirus B19 recombinant VP1 and VP2 capsid proteins were produced by a procaryotic pGEX expression plasmid to evaluate the humoral response by immunoblot assay in 14 patients with primary infection. The same concentrations of VP1 and VP2 recombinant proteins were used. This demonstrates that VP1 immunoglobulin M detection and/or VP1 immunoglobulin G seroconversion is a reliable marker of primary infections. Consequently, detection of antibodies to B19 VP1 might be helpful for identifying patients at risk for chronic B19 infection or patients who are susceptible to viral reinfection.
摘要
人细小病毒B19重组VP1和VP2衣壳蛋白由原核pGEX表达质粒产生，以通过免疫印迹法评估14例原发性感染患者的体液反应。使用相同浓度的VP1和VP2重组蛋白。这表明VP1免疫球蛋白M检测和/或VP1免疫球蛋白G血清转化是原发性感染的可靠标志物。因此，检测针对B19 VP1的抗体可能有助于识别有慢性B19感染风险的患者或易发生病毒再感染的患者。
相似文献
1
Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins.采用重组蛋白免疫印迹法检测原发性感染患者对人细小病毒B19的抗体反应。
Clin Diagn Lab Immunol. 1996 Mar;3(2):236-8. doi: 10.1128/cdli.3.2.236-238.1996.
2
Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection.
Mem Inst Oswaldo Cruz. 2001 May;96(4):507-13. doi: 10.1590/s0074-02762001000400011.
3
[Responsiveness of a new parvovirus B19 antigen produced in baculovirus expression system to B19-specific IgG and IgM antibodies in every epidemic, 1968, 1980, 1987 and 1992 in Japan].[杆状病毒表达系统产生的新型细小病毒B19抗原对1968年、1980年、1987年和1992年日本各次疫情中B19特异性IgG和IgM抗体的反应性]
Kansenshogaku Zasshi. 1995 May;69(5):546-52. doi: 10.11150/kansenshogakuzasshi1970.69.546.
4
A recombinant immunoblot and ELISA for detection of acute parvovirus B19 infection.
Zentralbl Bakteriol. 1994 Mar;280(4):526-33. doi: 10.1016/s0934-8840(11)80513-x.
5
Impaired gamma interferon responses against parvovirus B19 by recently infected children.近期感染儿童针对细小病毒B19的γ干扰素反应受损。
J Virol. 2000 Nov;74(21):9903-10. doi: 10.1128/jvi.74.21.9903-9910.2000.
6
Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.血友病性关节炎患者对B19细小病毒VP1和VP2线性表位的抗体反应。
J Med Virol. 2004 Apr;72(4):679-82. doi: 10.1002/jmv.20031.
7
Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity.使用在昆虫细胞中表达的重组病毒VP1抗原检测人细小病毒B19特异性IgM和IgG抗体，并通过检测抗体亲和力估计感染时间。
J Virol Methods. 1993 Sep;44(1):11-23. doi: 10.1016/0166-0934(93)90003-a.
8
Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins.针对细小病毒B19 VP1和VP2结构蛋白的构象表位和线性表位的差异性IgM反应。
J Med Virol. 2001 May;64(1):67-73. doi: 10.1002/jmv.1019.
9
Recombinant parvovirus B19 capsids as a new substrate for detection of B19-specific IgG and IgM antibodies by an enzyme-linked immunosorbent assay.
J Virol Methods. 1992 Sep;39(3):247-58. doi: 10.1016/0166-0934(92)90098-x.
10
A synthetic parvovirus B19 capsid protein can replace viral antigen in antibody-capture enzyme immunoassays.一种合成的细小病毒B19衣壳蛋白可在抗体捕获酶免疫测定中替代病毒抗原。
J Virol Methods. 1995 Sep;55(1):67-82. doi: 10.1016/0166-0934(95)00046-w.
引用本文的文献
1
Performance of Zika Assays in the Context of Toxoplasma gondii, Parvovirus B19, Rubella Virus, and Cytomegalovirus (TORCH) Diagnostic Assays.在弓形体、细小病毒 B19、风疹病毒和巨细胞病毒（TORCH）诊断检测中，寨卡病毒检测的性能。
Clin Microbiol Rev. 2019 Dec 11;33(1). doi: 10.1128/CMR.00130-18. Print 2019 Dec 18.
2
The 3' untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in nonpermissive cells.B19细小病毒衣壳蛋白mRNA的3'非翻译区在非允许细胞中抑制其自身mRNA的翻译。
J Virol. 1997 Dec;71(12):9482-9. doi: 10.1128/JVI.71.12.9482-9489.1997.
本文引用的文献
1
Candidate recombinant vaccine for human B19 parvovirus.人细小病毒B19候选重组疫苗。
J Infect Dis. 1993 May;167(5):1034-44. doi: 10.1093/infdis/167.5.1034.
2
Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity.使用在昆虫细胞中表达的重组病毒VP1抗原检测人细小病毒B19特异性IgM和IgG抗体，并通过检测抗体亲和力估计感染时间。
J Virol Methods. 1993 Sep;44(1):11-23. doi: 10.1016/0166-0934(93)90003-a.
3
Differential transcription, without replication, of non-structural and structural genes of human parvovirus B19 in the UT7/EPO cell as demonstrated by in situ hybridization.
J Gen Virol. 1994 Jun;75 ( Pt 6):1475-8. doi: 10.1099/0022-1317-75-6-1475.
4
Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV).用于人类血清细小病毒样病毒（SPLV）的单克隆抗体诊断检测法。
J Hyg (Lond). 1983 Aug;91(1):113-30. doi: 10.1017/s0022172400060095.
5
Human parvovirus infections in France.法国的人类细小病毒感染
Lancet. 1984 Jan 21;1(8369):160. doi: 10.1016/s0140-6736(84)90086-2.
6
Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis.从再生障碍性贫血危象患儿血清中分离出的人细小病毒B19的核苷酸序列和基因组结构
J Virol. 1986 Jun;58(3):921-36. doi: 10.1128/JVI.58.3.921-936.1986.
7
Translational regulation of B19 parvovirus capsid protein production by multiple upstream AUG triplets.
J Biol Chem. 1988 Aug 5;263(22):10922-6.
8
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.以谷胱甘肽S-转移酶融合形式在大肠杆菌中表达的多肽的一步纯化。
Gene. 1988 Jul 15;67(1):31-40. doi: 10.1016/0378-1119(88)90005-4.
9
Experimental parvoviral infection in humans.人类实验性细小病毒感染
J Infect Dis. 1985 Aug;152(2):257-65. doi: 10.1093/infdis/152.2.257.
10
Human parvovirus B19: ELISA and immunoblot assays.人细小病毒B19：酶联免疫吸附测定和免疫印迹分析
J Virol Methods. 1988 Jun;20(2):155-68. doi: 10.1016/0166-0934(88)90149-8.
Zotero 插件